drugset / Trial / NCT03443063
Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will be conducted to assess the effect of severe renal impairment on the pharmacokinetics of lemborexant after a single-dose administration.
Timeline
- Start
- 2018-02-07
- Primary completion
- 2018-08-24
- Completion
- 2018-08-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lemborexant | Small molecule | 10 mg | Oral |